Accueil>>Peptides>>Adrenomedullin (AM) (1-52), human

Adrenomedullin (AM) (1-52), human (Synonyms: Human adrenomedullin-(1-52)-NH2)

Catalog No.GC33955

L'adrénomédulline (AM) (1-52), humaine est un peptide de 52 acides aminés, qui affecte la prolifération cellulaire et l'angiogenèse dans le cancer.

Products are for research use only. Not for human use. We do not sell to patients.

Adrenomedullin (AM) (1-52), human Chemical Structure

Cas No.: 148498-78-6

Taille Prix Stock Qté
500μg
295,00 $US
En stock
1mg
478,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Adrenomedullin (AM) (1-52), human is a 52-amino acid peptide, which affects cell proliferation and angiogenesis in cancer.

To explore the effect of Adrenomedullin (AM) (1-52), human on astroglioma cells, CRT-MG cells are incubated in the absence or presence of Adrenomedullin (AM) (1-52), human (ADM1-52) for 48 h in a medium containing 1% FBS, and wound-healing assay is performed. The number of cells migrating to the wound region significantly increases in the ADM1-52-treated cells, in a dose-dependent manner, compared to the untreated cells[1].

[1]. Lim SY, et al. Transcriptional regulation of adrenomedullin by oncostatin M in human astroglioma cells: implications for tumor invasion and migration. Sci Rep. 2014 Sep 23;4:6444.

Avis

Review for Adrenomedullin (AM) (1-52), human

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Adrenomedullin (AM) (1-52), human

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.